For the second quarter of FY2023, BIOMARIN PHARMACEUTICAL ($NASDAQ:BMRN) reported total revenue of USD 595.3 million, which was a 11.5% increase from the same period last year. Net income for the quarter ending June 30 2023 also saw a notable increase from the same time-frame in FY2022, rising 102.6% to USD 56.0 million.
On Monday, BIOMARIN PHARMACEUTICAL reported total revenue of $595.3 million for the second quarter of fiscal year 2023. The increase came largely from sales of its approved products, which rose by 12% compared to the previous year. The company’s stock opened at $87.9 and closed at the same price, up by 0.4% from its previous closing price of $87.6. The increase in share price could be attributed to investors’ optimism regarding the company’s strong financial performance and long-term growth prospects.
This strong performance was driven primarily by higher product sales and cost savings initiatives. Overall, the report marked a strong financial performance for BIOMARIN PHARMACEUTICAL and was well received by investors. With continued focus on product innovation and cost optimization, the company is well-positioned to achieve further growth in the coming quarters. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Biomarin Pharmaceutical. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biomarin Pharmaceutical. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biomarin Pharmaceutical. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Biomarin Pharmaceutical are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale offers a comprehensive analysis of BIOMARIN PHARMACEUTICAL‘s fundamentals. Our Risk Rating indicates that BIOMARIN is a high risk investment in terms of financial and business aspects. We have detected 3 risk warnings in BIOMARIN’s income sheet, balance sheet, and non financial. If you’d like to learn more about the potential risks and rewards associated with investing in BIOMARIN, we suggest visiting our website and registering for a free account. You’ll be able to view detailed reports on the company’s financials and performance metrics, which should help you make an informed decision. More…
Risk Rating Analysis
Star Chart Analysis
The competition in the biopharmaceutical industry is fierce, with companies like Biomarin Pharmaceutical Inc, Sangamo Therapeutics Inc, Pfizer Inc, and Sanofi SA all vying for a piece of the pie. Each company has its own unique strengths and weaknesses, and it is up to the individual investor to decide which company is the best investment.
– Sangamo Therapeutics Inc ($NASDAQ:SGMO)
Sangamo Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative genomic medicines to treat serious and life-threatening diseases. The company has a market cap of $674.74 million and a negative return on equity of 32.96%. Sangamo Therapeutics is headquartered in Richmond, California.
Pfizer Inc. is an American multinational pharmaceutical corporation. It is one of the world’s largest pharmaceutical companies. The company was founded in 1849 by Charles Pfizer and Charles Erhart in New York City. Pfizer is a diversified company that operates in three main business segments: Pharmaceuticals, Animal Health, and Consumer Health.
Sanofi SA is a French multinational pharmaceutical company headquartered in Paris, France, that covers seven major therapeutic areas: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Sanofi Genzyme. As of 2020, Sanofi has 104,000 employees worldwide.
The company’s market cap is $98.97B as of 2022 and its ROE is 7.56%. Sanofi is a global leader in the pharmaceutical industry, with a strong presence in emerging markets. The company has a diversified product portfolio and is a major player in the diabetes market. Sanofi is also active in the vaccine market, with a number of innovative products in its portfolio.
BIOMARIN PHARMACEUTICAL has reported strong financial results for Q2 FY2023, with total revenue of USD 595.3 million and net income of USD 56.0 million. This represents a year-over-year increase of 11.5% and 102.6%, respectively. These figures demonstrate the company’s strong investment potential, as its financial performance continues to rise. This growth indicates a positive outlook for BIOMARIN PHARMACEUTICAL, and investors should consider it as an attractive option in the biopharmaceuticals industry.